One of the diagnostic tools we have for AD is the cerebrospinal fluid (CSF) analysis of p‐tau, Aβ42 and total Tau protein content, which reflects amyloidosis and tauopathy in the brain.10 This evidence concerns the gene MAPT and Alzheimer disease.